Neogen Past Earnings Performance

Past criteria checks 1/6

Neogen's earnings have been declining at an average annual rate of -34.1%, while the Medical Equipment industry saw earnings growing at 13.6% annually. Revenues have been growing at an average rate of 17.2% per year. Neogen's return on equity is 0.4%, and it has net margins of 1.3%.

Key information

-34.1%

Earnings growth rate

-33.8%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate17.2%
Return on equity0.4%
Net Margin1.3%
Next Earnings Update09 Apr 2024

Recent past performance updates

Statutory Profit Doesn't Reflect How Good Neogen's (NASDAQ:NEOG) Earnings Are

Jan 17
Statutory Profit Doesn't Reflect How Good Neogen's (NASDAQ:NEOG) Earnings Are

Recent updates

Neogen: All About Execution From Here On

Mar 26

Statutory Profit Doesn't Reflect How Good Neogen's (NASDAQ:NEOG) Earnings Are

Jan 17
Statutory Profit Doesn't Reflect How Good Neogen's (NASDAQ:NEOG) Earnings Are

Neogen Corporation Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts

Jan 12
Neogen Corporation Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts

Neogen Corporation (NASDAQ:NEOG) Investors Are Less Pessimistic Than Expected

Jan 09
Neogen Corporation (NASDAQ:NEOG) Investors Are Less Pessimistic Than Expected

Here's Why Neogen (NASDAQ:NEOG) Can Manage Its Debt Responsibly

Dec 06
Here's Why Neogen (NASDAQ:NEOG) Can Manage Its Debt Responsibly

Neogen (NASDAQ:NEOG) Has A Somewhat Strained Balance Sheet

Jul 12
Neogen (NASDAQ:NEOG) Has A Somewhat Strained Balance Sheet

Is There An Opportunity With Neogen Corporation's (NASDAQ:NEOG) 46% Undervaluation?

Jun 20
Is There An Opportunity With Neogen Corporation's (NASDAQ:NEOG) 46% Undervaluation?

Neogen (NASDAQ:NEOG) Has A Somewhat Strained Balance Sheet

Mar 25
Neogen (NASDAQ:NEOG) Has A Somewhat Strained Balance Sheet

Neogen introduces ready-to-use disinfectant Companion RTU for veterinary use

Oct 10

Neogen GAAP EPS of $0.05, revenue of $132.35M

Sep 27

Neogen drops 9% as merger with 3M’s food safety business closes

Sep 01

Broker Revenue Forecasts For Neogen Corporation (NASDAQ:NEOG) Are Surging Higher

Aug 21
Broker Revenue Forecasts For Neogen Corporation (NASDAQ:NEOG) Are Surging Higher

Neogen: Cut In Half, Still Some Questions

Aug 12

There May Be Reason For Hope In Neogen's (NASDAQ:NEOG) Disappointing Earnings

Aug 04
There May Be Reason For Hope In Neogen's (NASDAQ:NEOG) Disappointing Earnings

Neogen: Thesis Unchanged After Q4 And Full-Year Earnings

Aug 01

Neogen FQ4 2022 Earnings Preview

Jul 25

Zoetis, IDEXX named as buys in animal health space by Piper Sandler

Jul 13

Neogen announces pricing of $350M senior notes offering

Jul 07

Neogen: Safety Food Giant In The Making

Dec 15

Neogen (NASDAQ:NEOG) Will Want To Turn Around Its Return Trends

Dec 12
Neogen (NASDAQ:NEOG) Will Want To Turn Around Its Return Trends

Neogen (NASDAQ:NEOG) Will Want To Turn Around Its Return Trends

Sep 12
Neogen (NASDAQ:NEOG) Will Want To Turn Around Its Return Trends

Robust Valuation Leaves Neogen Little Room For Error After Mixed Results

Jul 27

There Are Reasons To Feel Uneasy About Neogen's (NASDAQ:NEOG) Returns On Capital

Jun 10
There Are Reasons To Feel Uneasy About Neogen's (NASDAQ:NEOG) Returns On Capital

We're Watching These Trends At Neogen (NASDAQ:NEOG)

Mar 09
We're Watching These Trends At Neogen (NASDAQ:NEOG)

Neogen Corporation's (NASDAQ:NEOG) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Feb 16
Neogen Corporation's (NASDAQ:NEOG) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Revenue & Expenses Breakdown
Beta

How Neogen makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:NEOG Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Nov 239191235427
31 Aug 23919-2733628
31 May 23822-2328426
28 Feb 23721-1321423
30 Nov 22631-1618520
31 Aug 225313614518
31 May 225274814217
28 Feb 225144915417
30 Nov 215035713317
31 Aug 214876212817
31 May 214686112216
28 Feb 214506112016
30 Nov 204336011415
31 Aug 204266111315
31 May 204185911415
29 Feb 204195911415
30 Nov 194176011214
31 Aug 194166011214
31 May 194146011113
28 Feb 194136210911
30 Nov 184106510911
31 Aug 184036610711
31 May 183986310511
28 Feb 183895810411
30 Nov 173825210211
31 Aug 17372469911
31 May 17358449410
28 Feb 17353419510
30 Nov 16341399310
31 Aug 16330379010
31 May 16321378710
29 Feb 16310368410
30 Nov 15301358110
31 Aug 15290347910
31 May 15283347710
28 Feb 1527232759
30 Nov 1426531759
31 Aug 1425629739
31 May 1424728718
28 Feb 1423628688
30 Nov 1322528658
31 Aug 1321628638
31 May 1320827618

Quality Earnings: NEOG has a large one-off loss of $17.0M impacting its last 12 months of financial results to 30th November, 2023.

Growing Profit Margin: NEOG became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NEOG's earnings have declined by 34.1% per year over the past 5 years.

Accelerating Growth: NEOG has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: NEOG has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (8.7%).


Return on Equity

High ROE: NEOG's Return on Equity (0.4%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.